---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-054508"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T17:05:33.832095+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease

## Summary
- Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.
- Galecto will not initiate Part B of GALLANT-1, reallocating resources to severe liver diseases as part of strategic alternative process.
- Two severe dose-limiting skin reactions occurred at 200 mg dose; no such reactions at the recommended 100 mg dose level.
- Galecto to supply GB1211 for an investigator-initiated Phase 2 trial at Providence Portland Medical Center expected in early 2024.
- Company plans to explore external options for partnering/funding further oncology activities for GB1211.

## SEC filing metadata
- accession: 0000950170-23-054508
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017023054508/0000950170-23-054508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017023054508/glto-20231023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-054508
- JSON: https://secwatch.observer/filing/0000950170-23-054508.json
- Plain text: https://secwatch.observer/filing/0000950170-23-054508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.